Latest debt-to-equity ratio
CRISPR Therapeutics Debt-to-equity ratio
Direct answer
CRISPR Therapeutics's debt-to-equity ratio is 44.87%.
The verified market snapshot reports 44.87%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked October 21, 2026.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 44.87%
Explore related company data
View CRISPR Therapeutics's market capitalizationView CRISPR Therapeutics's price-to-book ratioView CRISPR Therapeutics's return on equityView CRISPR Therapeutics's dividend yieldView CRISPR Therapeutics's 52-week price rangeView CRISPR Therapeutics's revenue growthView CRISPR Therapeutics's profit marginView all CRISPR Therapeutics key metricsReturn to CRISPR Therapeutics profile